Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases

    One billion people suffer from preventable, treatable diseases around the

    Statement by Dr. Paul Antony, medical director Global Health Progress

    TOYAKO, Japan, July 8 /CNW/ - "The worldwide pharmaceutical industry is
joining the World Health Organization (WHO) and the Drugs for Neglected
Diseases initiative (DNDi) in calling on the G-8 to recognize the importance
of neglected diseases as a global health threat and a major strain on the
economic viability and educational development of communities worldwide. We
urge the G-8 to finance successful treatment and prevention programs, to
support innovative strategies that address the challenging health gaps in
developing countries, and to fund research and development to develop improved
diagnostic, treatment and prevention options.

    "Most international attention is focused on HIV/AIDS, tuberculosis,
malaria and global health security. However, neglected tropical diseases -
most of which are preventable and treatable - remain major causes of death and
disability worldwide. These diseases receive less funding and less attention
while they decrease productivity, negatively affect quality of life and
increase poverty throughout the developing world.

    "Partnerships supported by the research-based biopharmaceutical companies
have provided billions of dollars in medicines, research and development,
supplies, distribution networks and other resources to fight neglected
diseases such as river blindness, trachoma, and lymphatic filariasis around
the world. In the process, we have lowered the cost for effective treatments
and made them available to hundreds of millions of people each year. Companies
have also made substantial contributions to building health care capacity in
developing countries, and are looking to implement more programs to address
remaining gaps in care.

    "However, the continuing threat of these diseases, which affect one in
six people worldwide, and the lack of access to existing treatment and
preventative measures makes it clear that there is more work to do.
Involvement by the global community, particularly the countries of the G-8, is
necessary to further efforts aimed at meeting the critical health challenges
of the developing world."

    Further information about efforts by research-based biopharmaceutical
companies, please visit For information about
neglected tropical diseases, visit WHO at or DNDi at

    About Global Health Progress

    The Global Health Progress initiative brings research-based
biopharmaceutical companies and global health leaders together to improve
health in the developing world. Through meaningful public-private partnerships
with others in the field, including policymakers in the developed and
developing world, multi-lateral institutions, non-governmental organizations,
and academe, we are helping to shape sustainable solutions that improve the
health of all people. For more information, please visit

For further information:

For further information: Mark Grayson, PhRMA, +1-202-835-3465,, for Global Health Progress Web Site: 

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890